News

Pfizer has announced the results from two phase 1 safety studies. One of PF-04360365, a humanized anti-amyloid monoclonal antibody, and another of dimebon in combination with donepezil HCl

Schering-Plough has extended the phase II study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. The

Targacept has showed positive top-line results from a double blind, placebo controlled, flexible dose phase 2b clinical trial of TC-5214. It is to be used as an augmentation

IBM has signed a five-year information technology services agreement with the Dow Chemical Company. As part of the agreement, IBM will help with the integration of Rohm and

BioWa has entered into a license agreement with Germany-based Merck (with access to BioWa’s Potelligen Technology platform) for the research, development and commercialization of their antibody therapies, with

Baptist Health has implemented Central Logic’s ForeFront Transfer solution across its statewide network of hospitals. The company would utilize the software to power its recently-established Patient Transfer Center.

Akaza Research announces the beta release of OpenClinica 3.0. It is expected to bring a host of new capabilities to the growing open source electronic data capture and

Vidacare has closed a $7.6 million private equity Series D1 financing. The financing would be used to launch Vidacare’s hematology/oncology product –  OnControl Bone Marrow System, and OnControl

Maxygen has completed its phase IIa clinical study in breast cancer patients, in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia (CIN). Phase IIa study were